Autoinjector company Oval Medical Technologies has presented results from two user studies in which Oval's proprietary autoinjector clearly demonstrated superiority compared with two well-known autoinjector devices currently on the market.
The Oval autoinjector is designed to be smaller, easier and safer to use than any other device currently available, and is applicable to a greater range of drugs.
The first study participants were presented with three training devices Oval Medical’s, MyClic and Humira and were asked to demonstrate their usage and then to rank all three in order of preference.
The second user study was held in Loughborough involving patients and same procedures as the Cambridge University study.
Oval claims that its device scored better than both competitor devices on all seven attributes that were tested by the potential patient users and all nine attributes evaluated by the sample of nurses.
Oval CEO Matthew Young said they are delighted to announce the results of these two user studies which show clearly that our autoinjector appeals to patients and is easy for them to use.
"Our proprietary autoinjector technology has a number of technical benefits in terms of low drug contamination, high fill volumes and the capacity to be applied to a wide range of products," Young said.
"These studies show that through world-class design we have combined these with features that will make life easier for patients as well."